Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-08-22
2011-10-04
Wen, Sharon (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387300, C530S387900, C530S388150, C424S130100, C424S133100, C424S137100, C424S145100
Reexamination Certificate
active
08030457
ABSTRACT:
Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
REFERENCES:
patent: 5545807 (1996-08-01), Surani et al.
patent: 5766886 (1998-06-01), Studnicka et al.
patent: 5869619 (1999-02-01), Studnicka
patent: 7029895 (2006-04-01), Glucksmann et al.
patent: 7261893 (2007-08-01), Veldman et al.
patent: 7300754 (2007-11-01), Abi Fadel et al.
patent: 7368531 (2008-05-01), Rosen et al.
patent: 7411051 (2008-08-01), Rosen et al.
patent: 7456264 (2008-11-01), Keler et al.
patent: 7482147 (2009-01-01), Glucksmann et al.
patent: 7776577 (2010-08-01), Kapeller-Libermann et al.
patent: 2002/0045571 (2002-04-01), Liu et al.
patent: 2003/0119038 (2003-06-01), Bingham et al.
patent: 2004/0009553 (2004-01-01), Glucksmann et al.
patent: 2004/0023243 (2004-02-01), Henry et al.
patent: 2004/0038242 (2004-02-01), Edmonds et al.
patent: 2004/0248177 (2004-12-01), Abi Fadel et al.
patent: 2005/0101529 (2005-05-01), Yue et al.
patent: 2005/0118625 (2005-06-01), Mounts
patent: 2005/0147612 (2005-07-01), Yayon et al.
patent: 2005/0197285 (2005-09-01), Rosen et al.
patent: 2006/0116508 (2006-06-01), Glucksmann et al.
patent: 2006/0147945 (2006-07-01), Edmonds et al.
patent: 2006/0223088 (2006-10-01), Rosen et al.
patent: 2006/0223090 (2006-10-01), Rosen et al.
patent: 2006/0246483 (2006-11-01), Rosen et al.
patent: 2007/0015696 (2007-01-01), Rosen et al.
patent: 2007/0037206 (2007-02-01), Rosen et al.
patent: 2007/0055056 (2007-03-01), Rosen et al.
patent: 2007/0082345 (2007-04-01), Ota et al.
patent: 2007/0224663 (2007-09-01), Rosen et al.
patent: 2008/0008697 (2008-01-01), Mintier et al.
patent: 2008/0103090 (2008-05-01), Rosen et al.
patent: 2008/0113930 (2008-05-01), Tan et al.
patent: 2009/0232795 (2009-09-01), Condra et al.
patent: 2009/0246192 (2009-10-01), Condra et al.
patent: 2010/0040610 (2010-02-01), Sitlani et al.
patent: 2010/0040611 (2010-02-01), Sparrow et al.
patent: 2010/0041102 (2010-02-01), Sitlani et al.
patent: 2010/0068194 (2010-03-01), Kim
patent: 2010/0068199 (2010-03-01), Liang et al.
patent: 2010/0136028 (2010-06-01), Sparrow et al.
patent: 2010/0150937 (2010-06-01), Sparrow et al.
patent: 2010/0166768 (2010-07-01), Sleeman et al.
patent: 2010/0233177 (2010-09-01), Yowe et al.
patent: 2011/0027287 (2011-02-01), Jackson et al.
patent: WO 93/12227 (1993-06-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 00/76310 (2000-12-01), None
patent: WO 01/31007 (2001-05-01), None
patent: WO 01/57081 (2001-08-01), None
patent: WO 01/98468 (2001-12-01), None
patent: WO 02/14358 (2002-02-01), None
patent: WO 02/46383 (2002-06-01), None
patent: WO 02/090526 (2002-11-01), None
patent: WO 02/102993 (2002-12-01), None
patent: WO 02/102994 (2002-12-01), None
patent: WO 2004/018649 (2004-03-01), None
patent: WO 2004/097047 (2004-11-01), None
patent: WO 2007/128121 (2007-11-01), None
patent: WO 2008/057457 (2008-05-01), None
patent: WO 2008/057457 (2008-05-01), None
patent: WO 2008/057458 (2008-05-01), None
patent: WO 2008/057458 (2008-05-01), None
patent: WO 2008/057459 (2008-05-01), None
patent: WO 2008/057459 (2008-05-01), None
patent: WO 2008/063382 (2008-05-01), None
patent: WO 2008/063382 (2008-05-01), None
patent: WO 2008/086395 (2008-07-01), None
patent: WO 2008/109871 (2008-09-01), None
patent: WO 2008/109871 (2008-09-01), None
patent: WO 2008/125623 (2008-10-01), None
patent: WO 2008/125623 (2008-10-01), None
patent: WO 2008/133647 (2008-11-01), None
patent: WO 2008/133647 (2008-11-01), None
patent: PCT/US2009/034775 (2009-02-01), None
patent: WO 2009/026558 (2009-02-01), None
patent: WO 2009/055783 (2009-04-01), None
patent: WO 2009/055783 (2009-04-01), None
patent: WO 2008/109871 (2009-07-01), None
patent: WO 2009/100297 (2009-08-01), None
patent: WO 2009/100318 (2009-08-01), None
patent: WO 2009/100318 (2009-08-01), None
patent: WO 2010/029513 (2010-03-01), None
patent: WO 2010/029513 (2010-03-01), None
patent: WO 2010/077854 (2010-07-01), None
patent: WO 2011/037791 (2011-03-01), None
patent: WO 2011/053759 (2011-05-01), None
patent: WO 2011/053783 (2011-05-01), None
patent: WO 2011/072263 (2011-06-01), None
U.S. Appl. No. 12/474,176, filed May 28, 2009, Jackson et al.
Abifadel et al. “Mutations in PCSK9 cause autosomal dominant hypercholesterolemia” Nat. Genet. 34, 154-156 (2003).
Anderson et al. Activation of the furin endoprotease is a multiple-step process: requirements for acidification and internal propeptide cleavage. EMBO J. 16, 1508-1518., 1997.
Benjannet et al. “The Proprotein Convertase (PC) PCSK9 is Inactivated by Furin and/or PC5/6A” J Biol Chem, Oct. 13, 2006, 281(41): 30561-30572.
Benjannet et al. “NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.” J Biol Chem, 2004, 279 (47): 48865-48875.
Berge et al. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler. Thromb. Vasc. Biol. (2006) 26, 1094-1100.
Bingham et al. Proapoptotic Effects of NARC 1 (= PCSK9), the Gene Encoding a Novel Serine Proteinase. Cytometry Part A, 2006, 69A: 1123-1131.
Bottomley et al. Structural and biochemical characterization of the wild type PCSK9/EGF-AB complex and natural FH mutants. J Biol Chem Nov. 2008.
Brown, M.S. & Goldstein, J.L. Lowering LDL—not only how low, but how long? Science 311, 1721-1723 (2006).
Brunger et al., Crystallography & NMR System: A new software suite for macromolecular structure determination,Acta Crystallogr D Biol Crystallogr54, 905-21 (1998).
Cameron et al., “Investigations on the evolutionary conservation of PCSK9 reveal a functionally important protrusion,”The FEBS Journal, pp. 1-13, 2008.
Cameron et al. “Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.” Hum. Mol. Genet. 15, 1551-1558 (2006).
CCP4. The CCP4 suite: programs for protein crystallography.Acta Crystallogr D. Biol Crystallogr50, 760-3 (1994).
Cohen et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264-1272 (2006).
Costet et al. Hepatic PCSK9 Expression is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c. Journal of Biological Chemistry, Mar. 2006. 281(10): 6211-6218.
Cunningham et al., “Structural and biophysical studies of PCSK9 and its mutants linked to familiar hypercholesterolemia,”Nature Structural&Molecular Biology, vol. 14, No. 5, pp. 413-419 (May 2007).
Dubuc et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 24, 1454-1459 (2004).
Duff et al. Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochemical Journal. Published online Feb. 5, 2009 as Manuscript BJ20082407.
EB 06682 Goat Anti-PCSK9 Antibody, Everest Biotech Online Catalogue, © 2007, auto-generated Sep. 7, 2007.
Fan et al. “Self-Association of Human PCSK9 Correlates with its LDLR-Degrading Activity”, Biochemistry, 2008, 47: 1631-1639.
Fu et al. (2000). Folding pathway mediated by an intramolecular chaperone. The inhibitory and chaperone functions of the subtilisin propeptide are not obligatorily linked. J. Biol. Chem. 275, 16871-16878.
Goldstein et al. “Familial hypercholesterolemia” in The Metabolic & Molecular Bases of Inherited Disease (eds. Scriver, C.S. et al.) 2863-2913 (McGraw-Hill, New York, 2001).
Goldstein, J.L. & Brown, M.S. The cholesterol quartet. Science 292, 1310-1312 (2001).
Graham et al. Antisense inhibition of proprotein convertase subtilis
Jackson Simon Mark
King Chadwick Terence
Shan Bei
Shen Wenyan
Amgen Inc.
Knobbe Martens Olson and Bear LLP
Wen Sharon
LandOfFree
Antigen binding proteins to proprotein convertase subtilisin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antigen binding proteins to proprotein convertase subtilisin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigen binding proteins to proprotein convertase subtilisin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4300105